Email updates

Keep up to date with the latest news and content from BMC Neurology and BioMed Central.

Open Access Research article

A single nucleotide polymorphism in the coding region of PGC-1α is a male-specific modifier of Huntington disease age-at-onset in a large European cohort

Patrick Weydt1*, Selma M Soyal2, G Bernhard Landwehrmeyer1, Wolfgang Patsch3 and For the European Huntington Disease Network

Author Affiliations

1 Neurology, Ulm University, 89081 Ulm, Germany

2 Laboratory Medicine, Paracelsus Medical University, 5020 Salzburg, Austria

3 Pharmacology, Paracelsus Medical University, 5020 Salzburg, Austria

For all author emails, please log on.

BMC Neurology 2014, 14:1  doi:10.1186/1471-2377-14-1

Published: 2 January 2014

Abstract

Background

Genetic modifiers are important clues for the identification of therapeutic targets in neurodegenerative diseases. Huntington disease (HD) is one of the most common autosomal dominant inherited neurodegenerative diseases. The clinical symptoms include motor abnormalities, cognitive decline and behavioral disturbances. Symptom onset is typically between 40 and 50 years of age, but can vary by several decades in extreme cases and this is in part determined by modifying genetic factors. The metabolic master regulator PGC-1α, coded by the PPARGC1A gene, coordinates cellular respiration and was shown to play a role in neurodegenerative diseases, including HD.

Methods

Using a candidate gene approach we analyzed a large European cohort (n = 1706) from the REGISTRY study for associations between PPARGC1A genotype and age at onset (AO) in HD.

Results

We report that a coding variant (rs3736265) in PPARGC1A is associated with an earlier motor AO in men but not women carrying the HD mutation.

Conclusions

These results further strengthen the evidence for a role of PGC-1α in HD and unexpectedly suggest a gender effect.

Keywords:
Genetic modifier; Gender effect; Neurodegeneration; Huntington disease